CIK 0001622229 · Large accelerated filer
Cogent Biosciences, Inc.
Sign in to watch- Ticker
- COGT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 465308248
- Phone
- 617-945-5576
- Business address
- 180 THIRD AVENUE, 4TH FLOOR, WALTHAM, MA
- Former names
- Unum Therapeutics Inc., Unum Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,689,493
- in 1 filing, $1.7M under 10b5-1 plans
Net −$1,689,493. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-10-01 | Ferrante Karen Jean Director | Grant or award · Stock Option (Right to Buy) | +759 | 759 | ||
| 2026-08-27 | Morris Arlene Director | Option exercise 10b5-1 | +41,927 | $5.64 | $236K | 41,927 |
| 2026-08-27 | Morris Arlene Director | Option exercise 10b5-1 | +3,583 | $2.52 | $9K | 45,510 |
| 2026-08-27 | Morris Arlene Director | Sale 10b5-1 | −42,349 | $37.09 | $1.6M | 3,161 |
| 2026-08-27 | Morris Arlene Director | Sale 10b5-1 | −3,161 | $37.54 | $119K | 0 |
| 2026-08-27 | Morris Arlene Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −41,927 | 2,773 | ||
| 2026-08-27 | Morris Arlene Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −3,583 | 0 | ||
| 2026-07-01 | Ferrante Karen Jean Director | Grant or award · Stock Option (Right to Buy) | +627 | 627 | ||
| 2026-06-09 | Shegog Todd Director | Grant or award · Stock Option (Right to Buy) | +17,901 | 17,901 | ||
| 2026-06-09 | Morris Arlene Director | Grant or award · Stock Option (Right to Buy) | +17,901 | 17,901 | ||
| 2026-06-09 | Ros Matthew Director | Grant or award · Stock Option (Right to Buy) | +17,901 | 17,901 | ||
| 2026-06-09 | Harwin Peter Evan Director | Grant or award · Stock Option (Right to Buy) | +17,901 | 17,901 | ||
| 2026-06-09 | Ferrante Karen Jean Director | Grant or award · Stock Option (Right to Buy) | +17,901 | 17,901 | ||
| 2026-06-09 | CAIN CHRISTOPHER W. Director | Grant or award · Stock Option (Right to Buy) | +17,901 | 17,901 | ||
| 2026-05-19 | Robbins Andrew R President and CEO | Gift | −160,000 | 497,503 | ||
| 2026-05-19 | Robbins Andrew R President and CEO | Gift | +160,000 | 160,000 | ||
| 2026-04-01 | Ferrante Karen Jean Director | Grant or award · Stock Option (Right to Buy) | +686 | 686 | ||
| 2026-03-31 | Fairmount Funds Management LLC Director | Conversion | +7,000,000 | 12,503,418 | ||
| 2026-03-31 | Fairmount Funds Management LLC Director | Sale | −7,000,000 | $34.66 | $242.6M | 5,503,418 |
| 2026-03-31 | Fairmount Funds Management LLC Director | Conversion · Series A Convertible Preferred Stock | −28,000 | 39,414 |
Page 1 of 7 · 131 trades